Generali Investments Cee, Investicni Spolecnost, A.S. Sarepta Therapeutics, Inc. Transaction History
Generali Investments Cee, Investicni Spolecnost, A.S.
- $1.22 Trillion
- Q2 2025
A detailed history of Generali Investments Cee, Investicni Spolecnost, A.S. transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Generali Investments Cee, Investicni Spolecnost, A.S. holds 105,326 shares of SRPT stock, worth $1.43 Million. This represents 0.15% of its overall portfolio holdings.
Number of Shares
105,326
Previous 2,000
5166.3%
Holding current value
$1.43 Million
Previous $128 Million
1311.06%
% of portfolio
0.15%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding SRPT
# of Institutions
501Shares Held
89.2MCall Options Held
1.39MPut Options Held
1.13M-
Black Rock Inc. New York, NY10.3MShares$141 Million0.04% of portfolio
-
Capital International Investors Los Angeles, CA9.06MShares$123 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.03MShares$123 Million0.01% of portfolio
-
State Street Corp Boston, MA4.07MShares$55.4 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X03.36MShares$45.8 Million0.12% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $1.19B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...